These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 25132665)

  • 61. Modeling the antiviral activity of ribavirin against hepatitis C virus in cell culture.
    Felmlee DJ; Xiao F; Baumert TF
    Hepatology; 2013 Oct; 58(4):1203-6. PubMed ID: 23703706
    [No Abstract]   [Full Text] [Related]  

  • 62. Predicting response to hepatitis C therapy.
    Oh TS; Rice CM
    J Clin Invest; 2009 Jan; 119(1):5-7. PubMed ID: 19104144
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Novel composed galactosylated nanodevices containing a ribavirin prodrug as hepatic cell-targeted carriers for HCV treatment.
    Craparo EF; Teresi G; Licciardi M; Bondí ML; Cavallaro G
    J Biomed Nanotechnol; 2013 Jun; 9(6):1107-22. PubMed ID: 23858977
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Photolabeling probes of ribavirin and EICAR.
    Wu Q; Qu F; Wan J; Xia Y; Peng L
    Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):999-1008. PubMed ID: 16248080
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Single- and repeat-dose toxicity of IDX14184, a nucleotide prodrug with antiviral activity for hepatitis C viral infection, in mice, rats, and monkeys.
    Luo S; Rush R; Standring D
    Hum Exp Toxicol; 2016 May; 35(5):472-90. PubMed ID: 26138064
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design.
    Wu JZ; Lin CC; Hong Z
    J Antimicrob Chemother; 2003 Oct; 52(4):543-6. PubMed ID: 12951339
    [No Abstract]   [Full Text] [Related]  

  • 67. Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV.
    Smith AAA; Zuwala K; Kryger MBL; Wohl BM; Guerrero-Sanchez C; Tolstrup M; Postma A; Zelikin AN
    Chem Sci; 2015 Jan; 6(1):264-269. PubMed ID: 28580095
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Nucleic acid triggered catalytic drug and probe release: a new concept for the design of chemotherapeutic and diagnostic agents.
    Ma Z; Taylor JS
    Bioorg Med Chem; 2001 Sep; 9(9):2501-10. PubMed ID: 11553492
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Molecular characterization of hepatitis C virus.
    Reed KE; Rice CM
    Curr Stud Hematol Blood Transfus; 1998; (62):1-37. PubMed ID: 9507802
    [No Abstract]   [Full Text] [Related]  

  • 70. Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions.
    Wu JZ; Walker H; Lau JY; Hong Z
    Antimicrob Agents Chemother; 2003 Jan; 47(1):426-31. PubMed ID: 12499231
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A decrease in Sendai virus infection potency by interactions with cationic thermo-responsive polymers.
    Yokoyama M; Okano T
    J Biomater Sci Polym Ed; 2001; 12(7):769-82. PubMed ID: 11587040
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Inhibitors of peptidyl proline isomerases as antivirals in hepatitis C and other viruses.
    Striker R; Mehle A
    PLoS Pathog; 2014 Nov; 10(11):e1004428. PubMed ID: 25375953
    [No Abstract]   [Full Text] [Related]  

  • 73. Characterization of Codon Usage Pattern in Hepatitis C Virus Subtype 6xa.
    Hou W
    Clin Lab; 2020 Aug; 66(8):. PubMed ID: 32776755
    [No Abstract]   [Full Text] [Related]  

  • 74. Recent advances in hepatitis C virus research.
    Omata M; Kato N
    J Gastroenterol; 1994 Jun; 29(3):377-82. PubMed ID: 8061810
    [No Abstract]   [Full Text] [Related]  

  • 75. HIV anti-latency treatment mediated by macromolecular prodrugs of histone deacetylase inhibitor, panobinostat.
    Zuwala K; Smith AAA; Tolstrup M; Zelikin AN
    Chem Sci; 2016 Mar; 7(3):2353-2358. PubMed ID: 29997778
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Macromolecular prodrugs of ribavirin: Polymer backbone defines blood safety, drug release, and efficacy of anti-inflammatory effects.
    Zuwala K; Riber CF; Løvschall KB; Andersen AHF; Sørensen L; Gajda P; Tolstrup M; Zelikin AN
    J Control Release; 2018 Apr; 275():53-66. PubMed ID: 29432822
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Advanced Prodrug Strategies in Nucleoside and Non-Nucleoside Antiviral Agents: A Review of the Recent Five Years.
    Sinokrot H; Smerat T; Najjar A; Karaman R
    Molecules; 2017 Oct; 22(10):. PubMed ID: 29035325
    [No Abstract]   [Full Text] [Related]  

  • 78. Highly active macromolecular prodrugs inhibit expression of the hepatitis C virus genome in the host cells.
    Ruiz-Sanchis P; Wohl BM; Smith AA; Zuwala K; Melchjorsen J; Tolstrup M; Zelikin AN
    Adv Healthc Mater; 2015 Jan; 4(1):65-8. PubMed ID: 25132665
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Macromolecular (pro)drugs with concurrent direct activity against the hepatitis C virus and inflammation.
    Wohl BM; Smith AA; Jensen BE; Zelikin AN
    J Control Release; 2014 Dec; 196():197-207. PubMed ID: 25451544
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Synthesis and evaluation of a new phosphorylated ribavirin prodrug.
    Dong SD; Lin CC; Schroeder M
    Antiviral Res; 2013 Jul; 99(1):18-26. PubMed ID: 23624267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.